表紙:CRO (医薬品開発業務受託機関) の世界市場:新型コロナウイルス感染症 (COVID-19) 以降の動向による混乱
市場調査レポート
商品コード
1008338

CRO (医薬品開発業務受託機関) の世界市場:新型コロナウイルス感染症 (COVID-19) 以降の動向による混乱

Post-COVID-19 Trends Disrupt the Global Contract Research Organization (CRO) Market

出版日: | 発行: Frost & Sullivan | ページ情報: 英文 67 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=115.27円
CRO (医薬品開発業務受託機関) の世界市場:新型コロナウイルス感染症 (COVID-19) 以降の動向による混乱
出版日: 2021年05月13日
発行: Frost & Sullivan
ページ情報: 英文 67 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 目次
概要

世界のCRO市場はここ数年は停滞した状態が続いていましたが、新型コロナウイルス感染症 (COVID-19) 用ワクチンの研究開発 (R&D) が急速に進められたため、2020年に大きく成長しました。分散型治験 (DCT) の実用化も始まり、企業合併・買収 (M&A) や新規参入も活発化しています。小規模なCROでも、希少疾患向け治療薬や慢性疾患向けバイオシミラーの開発、また機能サービスプロバイダー (FSP) モデルの導入を推し進め、事業の発展や提携先の確保・拡大に取り組みところが増えています。そして、患者中心性や治験の多様性に対する関心増大が、CRO各社や技術ベンダーに新たな成長機会をもたらしつつあります。

当レポートでは、世界のCRO (医薬品開発業務受託機関) 業界の展望と課題について分析し、COVID-19以降の市場の展望や成熟度、全体的な市場規模の動向見通し、セグメント別の詳細動向 (臨床/非臨床など)、主な市場促進・抑制要因、競争環境、昨今の主な動き (M&A/資本取引ほか)、今後の成長機会と目下の緊急課題、といった情報を取りまとめてお届けいたします。

目次

戦略的課題

成長機会の分析:世界のCRO市場

  • 世界のCRO市場:分析範囲
  • 世界のCRO市場の内訳
  • 世界のCRO市場:主要企業
  • 世界のCRO市場:サービスと利害関係者
  • 世界のCRO市場:ベンダー情勢
  • 世界のCRO市場:主な成長指標
  • 世界のCRO市場:成長促進要因
  • 世界のCRO市場:成長抑制要因
  • 世界のCRO市場:市場予測の前提条件
  • 世界のCRO市場:市場収益額の予測
  • 世界のCRO市場:競合環境
  • 世界のCRO市場:市場シェア
  • 主要CROの成長戦略
  • 世界のCRO市場:企業合併・買収 (M&A)

市場収益額の予測:世界のCRO市場

  • 分析手法
  • 非臨床CRO市場:主な前提条件
  • 非臨床CRO市場:市場収益額の予測
  • 非臨床CRO市場:市場収益額の予測、セグメント別
  • 臨床CRO市場:主な前提条件
  • 臨床CRO市場:市場収益額の予測
  • 臨床CRO市場:市場収益額の予測、地域別
  • 臨床CRO市場:市場収益額の予測、フェーズ別
  • 臨床CRO市場:市場収益額シェア、治療別

市場収益額の予測:地域別分析

  • 南北アメリカ:市場収益額の予測
  • 南北アメリカ:主な傾向
  • 欧州:市場収益額の予測
  • 欧州:主な傾向
  • 西太平洋:市場収益額の予測
  • 西太平洋:主な傾向
  • 他の国々 (RoW):市場収益額の予測
  • 他の国々 (RoW):主な傾向

成長機会:世界のCRO市場

  • 成長機会:概略
  • 成長機会 (1):製薬/バイオテクノロジー業界の中小企業向けのアジャイルFSPモデル (2021年)
  • 成長機会 (2):患者の多様性とRWE生成を確保するためのDCT (2021年)
  • 成長機会 (3):CGT向けのカスタム型バイオマーカーアッセイと治験デザイン (2021年)
  • 成長機会 (4):薬物・医療機器の組み合わせ型の治験向けの規制・データ管理サービス (2021年)

次のステップ

目次
Product Code: MFFF-52

Increased Focus on Patient Centricity and Diversity in Clinical Trials Provide Growth Opportunities for CROs and Technology Vendors

Frost & Sullivan presents post-COVID-19 growth opportunities and strategic imperatives in the contract research organization (CRO) market, covering the market's maturity, key participants, competitive landscape, and recent mergers and acquisitions. The study highlights key growth drivers and restraints, identifies initiatives by major global CROs, and estimates growth patterns for the next five years based on detailed analyses of drug and biologics interventional trials, outsourcing penetration rates, and cost variations. It further provides insights into the driving influences and challenges across regions and clinical development phases.

The plateaued CRO market experienced a sudden growth in 2020 due to the surge in research and development (R&D) efforts related to COVID-19 therapies and vaccines. The CRO market, fragmented with more than 1,000 participants, has two broad segments: nonclinical, which includes drug discovery and preclinical services, and clinical. Recent big acquisitions in the market may indicate a trend of future mergers or partnerships with integrated e-clinical platform providers as global CROs focus on building capabilities in innovative patient-centric clinical trial delivery models. Decentralized clinical trials (DCTs), while still at a nascent stage, are enabling newer participants to enter the clinical trial industry. Recent initiatives by the Decentralized Trials & Research Alliance to bring together industry participants, including CROs, pharma/biotech sponsors, and technology vendors, have increased awareness of DCTs globally and catapulted their adoption especially in North America. To adapt to DCTs, sponsors will increasingly rely on CROs to expedite the implementation of telemedicine components and remote monitoring solutions in clinical research due to inconsistencies in laws and regulations across the globe.

The rising need to maximize R&D productivity and global penetration has led to an increase in multicountry trial registrations by pharma/biotech sponsors. Several small biotech companies that support the development of therapies for rare/orphan diseases and biosimilars for chronic diseases are contributing to the CRO market growth. The continuous expansion in personalized medicine and cell and gene therapies, potency and biomarker assay complexities, and the need for adaptive trial designs is increasing outsourcing penetration to CROs. However, the shortage of skilled workforce with knowledge of the dynamic regulatory requirements to support complex therapies development can hinder the CRO market growth.

Patient-centric solutions and data-driven portfolios are fueling the adoption of functional service provider (FSP) models, even among small and midsize pharma companies. FSP partnerships enable them to rapidly scale their workforce to match business demand and distribute risk across programs or portfolios. Asia-Pacific customers are increasingly using outsourcing and insourcing FSP models in their partnerships to enhance traditional working models, resulting in greater value sharing, support, and access to expertise. Lastly, the need to develop highly efficacious therapies through innovation has boosted the growth of drug-device combination therapies, leading to more partnerships between medtech participants, CROs, and pharma companies for clinical development programs.

Table of Contents

Strategic Imperatives

  • Why Is It Increasingly Difficult to Grow?
  • The Strategic Imperative 8™
  • The Impact of the Top Three Strategic Imperatives on the Global Contract Research Organization (CRO) Industry
  • Growth Opportunities Fuel the Growth Pipeline Engine™

Growth Opportunity Analysis-Global CRO Market

  • Global CRO Market Scope of Analysis
  • Global CRO Market Segmentation
  • Key Competitors for the Global CRO Market
  • Global CRO Market-Services and Stakeholders
  • Global CRO Market-Vendor Landscape
  • Key Growth Metrics for the Global CRO Market
  • Growth Drivers for the Global CRO Market
  • Growth Restraints for the Global CRO Market
  • Global CRO Market-Forecast Assumptions
  • Global CRO Market-Revenue Forecast
  • Global CRO Market-Competitive Environment
  • Global CRO Market-Market Share
  • Growth Strategies of Top CROs
  • Growth Strategies of Top CROs (continued)
  • Global CRO Market-Mergers and Acquisitions

Revenue Forecast-Global CRO Market

  • Revenue Forecast Methodology
  • Nonclinical CRO Market-Key Market Assumptions
  • Nonclinical CRO Market-Revenue Forecast
  • Nonclinical CRO Market-Revenue Forecast by Segment
  • Nonclinical CRO Market-Revenue Forecast Discussion
  • Clinical CRO Market-Key Market Assumptions
  • Clinical CRO Market-Key Market Assumptions (continued)
  • Clinical CRO Market-Revenue Forecast
  • Clinical CRO Market-Revenue Forecast by Region
  • Clinical CRO Market-Percentage Revenue Forecast by Region
  • Clinical CRO Market-Revenue Forecast by Phase
  • Clinical CRO Market-Percentage Revenue Forecast by Phase
  • Clinical CRO Market-Revenue Share by Therapy
  • Clinical CRO Market-Revenue Forecast Discussion
  • Clinical CRO Market-Revenue Forecast Discussion (continued)

Revenue Forecast-Regional Analysis

  • Revenue Forecast-Americas
  • Key Trends-Americas
  • Revenue Forecast-Europe
  • Key Trends-Europe
  • Revenue Forecast-Western Pacific
  • Key Trends-Western Pacific
  • Revenue Forecast-ROW
  • Key Trends-ROW

Growth Opportunity Universe-Global CRO Market

  • Growth Opportunity Universe Summary
  • Growth Opportunity 1-Agile FSP Model for Small and Midsize Pharma/Biotech Companies, 2021
  • Growth Opportunity 1-Agile FSP Model for Small and Midsize Pharma/Biotech Companies, 2021 (continued)
  • Growth Opportunity 2-DCTs to Ensure Patient Diversity and Real-world Evidence Generation, 2021
  • Growth Opportunity 2-DCTs to Ensure Patient Diversity and Real-world Evidence Generation, 2021 (continued)
  • Growth Opportunity 3-Customized Biomarker Assays and Trial Designs for CGT, 2021
  • Growth Opportunity 3-Customized Biomarker Assays and Trial Designs for CGT, 2021 (continued)
  • Growth Opportunity 4-Regulatory and Data Management Services for Drug-Device Combination Clinical Trials, 2021
  • Growth Opportunity 4-Regulatory and Data Management Services for Drug-Device Combination Clinical Trials, 2021 (continued)

Next Steps

  • Your Next Steps
  • Why Frost, Why Now?
  • List of Exhibits
  • List of Exhibits (continued)
  • Legal Disclaimer